On December 14, the President & CEO of Evoke Pharma (EVOK), David Gonyer, sold shares of EVOK for $209.8K.
This is Gonyer’s first transaction since reporting a Buy transaction on MGEN back in February 2017 In addition to David Gonyer, one other EVOK executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.06 and a one-year low of $0.79. EVOK’s market cap is $77.85 million and the company has a P/E ratio of -5.90. Currently, Evoke Pharma has an average volume of 147.28K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D’Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
